



(12) Translation of
European patent specification

(11) NO/EP 3302549 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/395 (2006.01)
A61K 31/40 (2006.01)
A61K 31/496 (2006.01)
A61P 35/02 (2006.01)
C07K 16/28 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2019.09.16

(80) Date of The European Patent Office Publication of the Granted Patent 2019.07.03

(86) European Application Nr. 16725104.0

(86) European Filing Date 2016.05.23

(87) The European Application's Publication Date 2018.04.11

(30) Priority 2015.05.26, EP, 15169199

(84) Designated Contracting States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR

Designated Validation States: MA

(73) Proprietor F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Sveits

(72) Inventor KLEIN, Christian, Chapfstrasse 26B, 8906 Bonstetten, Sveits
HERTING, Frank, An der Freiheit 29a, 82377 Penzberg, Tyskland
DANGL, Markus, Unterer Flurweg 7, 82402 Seeshaupt, Tyskland

(74) Agent or Attorney PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54) Title **COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BCL-2 INHIBITOR AND A MDM2 INHIBITOR**

(56) References Cited:
WO-A1-2012/080389
Dangl et al.: "Abstract 5505: Synergistic anticancer activity of clinical stage, non-genotoxic apoptosis inducing agents RG7388 (MDM2 antagonist) and ABT-199 (GDC-0199, BCL2 inhibitor) in p53 wild-type AML tumor models", AACR Annual Meeting 2014 , April 2014 (2014-04), XP002759669, Retrieved from the Internet: URL:http://cancerres.aacrjournals.org/content/74/19_Supplement/5505 [retrieved on 2016-07-08]
Rongqing et al.: "Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199)", 56th Annual Meeting of the American-Society-of-Hematology , December 2014 (2014-12), XP002759670, Retrieved from the Internet: URL:www.bloodjournal.org/content/124/21/21_62 [retrieved on 2016-07-08]

Herting et al.: "1780 Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity", 56th ASH Annual Meeting and Exposition , December 2014 (2014-12), XP002759668, Retrieved from the Internet: URL:<https://ash.confex.com/ash/2014/webprogram/Paper67783.html> [retrieved on 2016-07-08]

Herting et al.: "3915 Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263", 52nd ASH Annual Meeting and Exposition , December 2010 (2010-12), XP002759667, Retrieved from the Internet: URL:<https://ash.confex.com/ash/2010/webprogram/Paper26413.html> [retrieved on 2016-07-08]

Ma et al.: "ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.", 2014 ASCO Annual Meeting , June 2014 (2014-06), XP002759665, Retrieved from the Internet: URL:<http://meetinglibrary.asco.org/content/132375-144> [retrieved on 2016-07-08]

Roberts et al.: "325 Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)", 56th ASH Annual Meeting and Exposition , December 2014 (2014-12), XP002759664, Retrieved from the Internet: URL:<https://ash.confex.com/ash/2014/webprogram/Paper71378.html> [retrieved on 2016-07-07]

Flinn et al.: "4687 Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia", 56th ASH Annual Meeting and Exposition , December 2014 (2014-12), XP002759666, Retrieved from the Internet: URL:<https://ash.confex.com/ash/2014/webprogram/Paper75779.html> [retrieved on 2016-07-08]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Farmasøytisk sammensetning omfattende en kombinasjon av et humanisert B-Ly1-antistoff som er afukosylert med en mengde fukose på 60 % eller mindre av den totale mengden oligosakkarider ved Asn297, og 4-(4-{[2-(4-klorfenyl)-4,4-dimetylsykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmetyl)amino]fenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid (GDC-0199, ABT199) og 4-{[(2R,3S,4R,5S)-4-(4-klor-2-fluor-fenyl)-3-(3-klor-2-fluor-fenyl)-4-cyano-5-(2,2-dimetyl-propyl)-pyrrolidin-2-karbonyl]-amino}-3-metoksy-benzosyre (RG7388) eller et salt derav for anvendelse i behandling av kreft.
2. Farmasøytisk sammensetning for anvendelse ifølge krav 1, hvori kreften er en CD20-uttrykkende kreft.
3. Farmasøytisk sammensetning for anvendelse ifølge krav 2, hvori den CD20-uttrykkende kreften er et lymfom eller lymfatisk leukemi.
4. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1–3, hvori det afukosylerte anti-CD20-antistoffet er obinutuzumab.
5. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1–4, hvori ytterligere ett eller flere andre cytotoksiske midler, kjemoterapeutiske midler eller anti-kreftmidler, eller forbindelser eller ioniserende stråling som forsterker effekten av slike midler, administreres.